Introduction:
The biologics market in the United Kingdom is experiencing significant growth, driven by an increasing demand for innovative treatments and advancements in biotechnology. According to a recent report, the biologics market in the UK is expected to reach £5 billion by 2026, representing a CAGR of 8.5% from 2021 to 2026.
Top 10 Biologic Access in United Kingdom 2026:
1. AbbVie: AbbVie is a leading biopharmaceutical company with a strong presence in the UK market. The company’s biologics portfolio includes top-selling drugs such as Humira and Imbruvica, which have gained widespread access in the UK healthcare system.
2. Roche: Roche is another key player in the biologics market in the UK, with a diverse portfolio of biologic drugs across various therapeutic areas. The company’s biologics division has seen significant growth in recent years, with drugs like Rituxan and Avastin driving market share.
3. Amgen: Amgen is a global biotechnology company known for its innovative biologic treatments. In the UK, Amgen’s biologics portfolio includes drugs like Enbrel and Neulasta, which have gained popularity among healthcare providers and patients.
4. Pfizer: Pfizer is a leading pharmaceutical company with a strong presence in the UK biologics market. The company’s biologics division has seen steady growth, with drugs like Xeljanz and Ibrance gaining access in the UK healthcare system.
5. Novartis: Novartis is a multinational pharmaceutical company with a growing biologics portfolio in the UK. Drugs like Cosentyx and Lucentis have gained significant market share, driving the company’s success in the biologics market.
6. Johnson & Johnson: Johnson & Johnson is a diversified healthcare company with a strong presence in the UK biologics market. The company’s biologics division includes drugs like Stelara and Remicade, which have gained access in the UK healthcare system.
7. Bristol Myers Squibb: Bristol Myers Squibb is a global biopharmaceutical company with a growing presence in the UK biologics market. Drugs like Opdivo and Eliquis have gained popularity among healthcare providers and patients, driving the company’s success in the market.
8. Merck: Merck is a leading pharmaceutical company with a diverse biologics portfolio in the UK. The company’s biologics division includes drugs like Keytruda and Gardasil, which have gained access in the UK healthcare system.
9. AstraZeneca: AstraZeneca is a multinational pharmaceutical company with a strong presence in the UK biologics market. The company’s biologics portfolio includes drugs like Tagrisso and Lynparza, which have gained popularity among healthcare providers and patients.
10. Gilead Sciences: Gilead Sciences is a biopharmaceutical company known for its innovative biologic treatments. In the UK, Gilead’s biologics portfolio includes drugs like Truvada and Harvoni, which have gained access in the UK healthcare system.
Insights:
The biologics market in the United Kingdom is poised for continued growth, driven by an increasing demand for innovative treatments and advancements in biotechnology. According to market research, the UK biologics market is expected to grow at a CAGR of 8.5% from 2021 to 2026, reaching £5 billion by 2026. Key players like AbbVie, Roche, and Amgen are expected to maintain their strong presence in the market, with a focus on expanding access to biologic treatments for patients in the UK. Overall, the future looks bright for the biologics market in the United Kingdom, with opportunities for growth and innovation on the horizon.
Related Analysis: View Previous Industry Report
